(Q38086054)

28 August 2017

title

Tumor-bowel fistula: what radiologists should know (English)

1 reference

28 August 2017

Sree Harsha Tirumani

1

1 reference

28 August 2017

Juan C Baez

2

1 reference

28 August 2017

Jyothi P Jagannathan

3

1 reference

28 August 2017

Atul B Shinagare

4

1 reference

28 August 2017

Nikhil H Ramaiya

5

1 reference

28 August 2017

publication date

1 October 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

38

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

1014-1023

1 reference

Acquired gastrointestinal fistulas: classification, etiologies, and imaging evaluation

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Fistulas in malignant gynecologic disease: etiology, imaging, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Ovarian carcinoma complicated by sigmoid colon fistula formation: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Malignant coloduodenal fistulas-review of literature and case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Jejunocolic fistula associated with an intestinal T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Can we predict vesicovaginal or rectovaginal fistula formation in patients with stage IVA cervical cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Liver abscess complicating transcatheter arterial embolization: a rare but serious complication. A retrospective study after 3878 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Delayed spontaneous hepatogastric fistula formation following transcatheter arterial embolisation and radiotherapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Gastrointestinal perforation due to bevacizumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-013-9987-6

10.1007/S00261-013-9987-6

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference